Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 10, 2021 09:15 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

OCALA, Fla., Feb. 10, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the Dutch Health and Youth Care Inspectorate (IGJ) has approved treatment for six...
February 05, 2021 14:21 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech完成并结束了ATM工具；当前资金有望满足当前临床试验的需求

佛罗里达州奥卡拉, Feb. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（纽约证券交易所股票代码：AIM）今天宣布已经完成了其市价（ATM）工具，并结束了ATM的股票发行协议（EDA）。管理层相信，根据公司当前的财务状况，公司有足够的资金来满足其预期的运营现金需求，并在未来大约二十四个月内都为当前的临床试验提供资金。 ...
February 05, 2021 14:21 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech、進行中の臨床試験ニーズに対応する資金を確保済みとして、ATMファシリティを完了、クローズ

フロリダ州オカラ発, Feb. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) は本日、アットザマーケット (ATM) ファシリティを完了し、ATMエクイティ･ディストリビューション契約 (EDA)...
February 05, 2021 06:50 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials

OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM’s Equity...
January 29, 2021 06:55 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

OCALA, Fla., Jan. 29, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has entered into a sponsorship agreement with the Centre for Human Drug Research...
January 15, 2021 06:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

OCALA, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday,...
January 11, 2021 06:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week’s planned investor conference call will be...
January 06, 2021 06:45 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen

OCALA, Fla., Jan. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that the active AMP-511 Expanded Access Program (EAP) has dosed its first COVID-19 “Long...
December 24, 2020 09:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’

OCALA, Fla., Dec. 24, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announced today that the post-COVID-19 “Long Hauler” portion of the active AMP-511 Expanded Access Program...
December 22, 2020 09:54 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTechのAmpligen、FDAからすい臓がん治療の希少疾病用医薬品指定を受ける

フロリダ州オカラ発, Dec. 22, 2020 (GLOBE NEWSWIRE) -- 免疫障害、ウイルス性疾患、複数のタイプのがんの治療法の研究開発に注力する免疫製薬会社のAIM ImmunoTech Inc. (NYSE American:AIM) は本日、同社のAmpligen (リンタトリモド)...